Next Article in Journal
The Interplay Between Body Weight and the Onset of Puberty
Previous Article in Journal
Mediating Role of Parental Support in the Relationship Between Immigrant Mothers’ Mental Health and Adolescents’ Self-Esteem
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Children
Volume 12
Issue 6
10.3390/children12060678
children-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study

by
Buddhaporn Prasertsakul
1,2,
Phanthila Sitthikarnkha
3,*,
Chetta Ngamjarus
4,
Chaniya Jakeaw
5 and
Sumitr Sutra
3
1
Department of Pediatrics, Chum Phae Hospital, Khon Kaen 40130, Thailand
2
The Office of Disease Prevention and Control Region 7, Department of Disease Control, Ministry of Public Health, Khon Kaen 40000, Thailand
3
Department of Pediatrics, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Road, Muang, Khon Kaen 40002, Thailand
4
Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen University, Khon Kaen 40002, Thailand
5
Department of Pediatrics, Khon Kaen Hospital, Khon Kaen 40000, Thailand
*
Author to whom correspondence should be addressed.
Children 2025, 12(6), 678; https://doi.org/10.3390/children12060678
Submission received: 11 April 2025 / Revised: 21 May 2025 / Accepted: 23 May 2025 / Published: 24 May 2025
(This article belongs to the Section Pediatric Infectious Diseases)
Browse Figure
Versions Notes

Abstract

Background/Objectives: After pandemic of COVID-19, there were increased the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C), as reported by the Centers for Disease Control and Prevention (CDC). However, it remains unclear which specific factors link MIS-C to COVID-19 following infection. This study aims to investigate the factors associated with MIS-C in children infected with COVID-19. Methods: A multicenter-matched case-control study was conducted across Chum Phae, Khon Kaen, and Srinagarind Hospitals, Thailand. We included patients under 21 years old from those hospitals from January 2021 to February 2024. The cases were patients diagnosed with MIS-C, while the controls had a history of COVID-19 infection but had not been diagnosed with MIS-C at least 3 months post-infection. The matching criteria for cases and controls, in a 1:2 ratio, included gender and age. The association between various factors and MIS-C was examined using conditional logistic regression. Results: A total of 34 MIS-C cases were matched with 68 controls. We found that antiviral therapy administered during COVID-19 infection was linked to a reduced risk of MIS-C development, with an adjusted odds ratio of 0.06 (95% CI: 0.02–0.20). However, this study found no association between COVID-19 vaccination and nutritional status in the development of MIS-C. Conclusions: The administration of antiviral treatment during COVID-19 infection was associated with a diminished incidence of MIS-C.

1. Introduction

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), or COVID-19, has been identified since December 2019. It causes a highly contagious infection that quickly spreads globally. The World Health Organization (WHO) declared a global pandemic in March 2020 [1]. Subsequently, in April 2020, cases of children presenting with symptoms similar to Kawasaki disease were reported [2]. The National Health Service (NHS) of the United Kingdom warned that these symptoms were associated with COVID-19 in children. Later, countries in the European Union and the United States reported a syndrome characterized by multisystem inflammatory symptoms in pediatric patients [3], which could be severe enough to cause hypotension requiring vasopressor support and necessitate mechanical ventilation due to cardiovascular involvement rather than respiratory failure [4]. The WHO defined this condition as a temporary multisystem inflammatory syndrome in children and adolescents related to COVID-19. The Centers for Disease Control and Prevention (CDC) in the United States termed it Multisystem Inflammatory Syndrome in Children (MIS-C). The Royal College of Pediatrics and Child Health (RCPCH) in the United Kingdom referred to it as Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) [4].
Current studies indicate that MIS-C typically occurs after COVID-19 infection rather than during the active infection. The clinical manifestations of MIS-C exhibited notable similarities to various other conditions, particularly Kawasaki disease and toxic shock syndrome [5], which can lead to delays and confusion in diagnosis during the initial stages. Following an overwhelming inflammatory response, the clinical manifestations and indicators of multiorgan dysfunction will promptly become evident. Timely diagnosis of MIS-C is essential for healthcare professionals; equally important is the identification of factors linked to the onset of MIS-C subsequent to COVID-19 infection. Understanding these factors can aid in the development of targeted interventions and improve patient outcomes. There was a study of MIS-C occurring after COVID-19 vaccination in children, with varying efficacy depending on the type of vaccine [6]. However, some studies found that vaccination against SARS-CoV-2 infection played an important role in reducing the risk of developing MIS-C [7,8].
The data on associated factors for MIS-C development among children were scarce. Understanding the factors could enable better surveillance, timely diagnosis, and treatment of this syndrome. Additionally, early intervention could potentially reduce mortality rates associated with delayed diagnosis. Thus, the primary objective of this study was to explore the factors associated with MIS-C in children infected with COVID-19.

2. Materials and Methods

2.1. Study Design and Participants

A multicenter matched case-control study was conducted involving individuals under 21 years of age who had been hospitalized at Chum Phae Hospital, Khon Kaen Hospital, and Srinagarind Hospital from 1 January 2021 to 29 February 2024. These hospitals have classified the hospital level as secondary, tertiary, and super-tertiary, respectively. The cases in this study included patients diagnosed with MIS-C, while the controls were individuals with a history of COVID-19 infection who had not been diagnosed with MIS-C at least three months post-infection. The matching criteria for cases and controls were established in a 1:2 ratio, considering factors such as gender and age. Participants who were diagnosed with Kawasaki disease, staphylococcal scalded skin syndrome, and toxic shock syndrome were systematically excluded from the study. Excluding these conditions will minimize confounding variables and ensure that the results were solely attributable to the primary factors being studied.
A sample size was calculated for a matched case-control study utilizing the appropriate formula [9]. From the research by Zambrano et al. [10], we determined the proportion of exposure to be 0.049, with an odds ratio (OR) of 8. The significance level for Type I error was established at 0.05, while the probability of Type II error was determined to be 0.2. Consequently, we arrived at a sample size of 34 cases and 68 controls.

2.2. Data Collection

Cases were defined as patients diagnosed with MIS-C based on the consensus of multidisciplinary pediatricians and the diagnostic criteria established by the Centers for Disease Control and Prevention (CDC), which includes the following criteria: (1) Body temperature above 38 °C persisting for over 24 h or subjective fever lasting longer than 24 h, (2) laboratory findings of inflammation, demonstrated by increased levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactate dehydrogenase (LDH), interleukin-6 (IL-6), and neutrophils, coupled with reduced levels of lymphocytes and albumin, (3) Multisystem involvement is characterized by clinically severe illness that necessitates hospitalization and affects at least two organ systems, which may include cardiac, renal, respiratory, hematologic, gastrointestinal, or dermatologic systems, (4) symptoms sufficiency severe enough to require hospitalization, and 5) Evidence supporting a prior COVID-19 infection within four weeks preceding the onset of symptoms can be established by any one of the following: a positive result for SARS-CoV-2 via reverse transcription polymerase chain reaction (RT-PCR), the presence of antibodies against SARS-CoV-2, an antigen test, or documented exposure to COVID-19 [11].
The participants in the control group were hospitalized patients with a history of SARS-CoV-2 infection confirmed by positive antigen test kit, or RT-PCR but did not develop MIS-C within three months post-infection. Controls were selected and matched to cases in a 1:2 ratio based on age (within one year) and gender. The management of pediatric patients who were hospitalized due to COVID-19 was performed in adherence to the Thai National Treatment Guidelines for COVID-19 across all hospitals [12].
We collected extensive data in both the case and control groups on various significant factors, including the patients’ age at the time of COVID-19 infection, gender, nutritional status, history of COVID-19 vaccination, clinical symptoms noted at the time of admission, laboratory findings, and treatment strategies applied during COVID-19 infection.

2.3. Statistical Analyses

Categorical variables were presented as frequencies and percentages, and differences between the two groups were compared using Pearson’s Chi-squared test or Fisher’s exact test. Median and interquartile ranges (IQR) were used to describe the outcomes of continuous variables, and the Wilcoxon rank sum test was used to calculate differences in medians of certain continuous variables. The associated factors of MIS-C was investigated using both simple and multiple conditional regression analyses, with results presented as crude and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). The multivariable conditional logistic regression model incorporated variables including nutritional status, vaccination history, and the administration of antiviral medications. R Statistical Software Version 4.4.1 (R Core Team 2024) was used to analyze all data in this study.

3. Results

3.1. Demographic Data

A total of 34 patients diagnosed with MIS-C were enrolled as cases in this study. Among these patients, 16 (47.1%) had no prior documented cases of SARS-CoV-2 infection. However, seven of these individuals tested positive for SARS-CoV-2 via RT-PCR, indicated by low cycle threshold values, suggesting a prior COVID-19 infection. Additionally, four patients exhibited the presence of anti-nucleocapsid (anti-N) antibodies against SARS-CoV-2, indicating past COVID-19 infection rather than vaccination-derived immunity. Furthermore, five patients reported documented exposure to COVID-19 within four weeks prior to the onset of their clinical symptoms. All these MIS-C patients were classified as cases. A total of 68 hospitalized patients with a history of SARS-CoV-2 infection were recruited in the control group. Case and control patients were well-matched in gender and age.
Malnutrition was found to be more common among participants in the case group compared to those in the control group. Notably, the control group had two individuals with a history of asthma, whereas no participants in the case group reported such a history. The vaccination history for the case group was recorded before the diagnosis of MIS-C. In contrast, in the control group, vaccination history was documented both before and three months after SARS-CoV-2 infection. The individuals participating in this study exclusively utilized the mRNA-based vaccine developed by the Pfizer-BioNTech COVID-19 Vaccine® (Kalamazoo, MI, USA). The case and control groups consisted of a small number of participants who had received at least two doses of the vaccine, with five individuals (14.7%) in the case group and five individuals (7.4%) in the control group. There is no significant difference in duration after the first, second, and last doses of the vaccine and the occurrence of COVID-19 infection (Table 1).

3.2. Clinical Characteristics

Clinical symptoms during the SARS-CoV-2 infection period in the control group (68 controls) showed greater systemic involvement compared to the case group (18 cases) as follows: upper respiratory tract symptoms were present in 64.2% versus 33.3%, lower respiratory tract symptoms in 60.3% versus 27.8%, gastrointestinal symptoms in 20.6% versus 11.1%, and neurological symptoms in 22.1% versus 0%. In terms of the severity of SARS-CoV-2 infection, most cases in both groups exhibited mild symptoms. Complications, including respiratory failure, acute laryngotracheitis, and febrile seizures, were noted in approximately 5% of both groups. In the case group, one patient experienced respiratory failure requiring mechanical ventilation, while in the control group, three patients had febrile seizures, and one patient had acute laryngotracheitis (Table 2).
Laboratory findings during the SARS-CoV-2 infection period in both groups were typically within normal ranges. However, the median absolute lymphocyte count was lower in the MIS-C group, with values of 996 (IQR 882, 1660) compared to 2949 (IQR 1907, 4551) cells/mm3 in the control group (p-value 0.041). Additionally, the median platelet count in the MIS-C group was lower than that in the control group, with values of 145,000 (IQR 140,000, 176,000) versus 287,000 (IQR 253,000, 317,500) cells/mm3 (p-value 0.011). There were no statistically significant differences observed in the total white blood cell count and absolute neutrophil count between the two groups (Figure 1 and Table 2).
In the case group, only 8 individuals (44.4%) received antiviral drugs during their SARS-CoV-2 infection, while 18 had a history of infection. One individual received a 10-day course of remdesivir due to respiratory failure. In the control group, 53 individuals (77.9%) received antiviral drugs, all of whom were treated with favipiravir (Table 2).

3.3. Factors Associated with MIS-C

Due to the significant amount of missing clinical and laboratory data during the infection period, these data were not analyzed for the factors of interest. Children who receive antiviral therapy, including favipiravir and remdesivir, exhibit a reduction in the risk of MIS-C, with an adjusted OR of 0.06 (95% CI: 0.02–0.20). The nutritional status, encompassing malnutrition, overweight, and obesity, demonstrates adjusted ORs of 0.79 (95% CI: 0.23–2.70), 0.93 (95% CI: 0.22–3.96), and 0.44 (95% CI: 0.07–2.92), respectively. Furthermore, children who received one dose or at least two doses of the SARS-CoV-2 vaccine have adjusted ORs of 0.28 (95% CI: 0.06–1.27) and 1.83 (95% CI: 0.34–9.89), respectively (Table 3).

4. Discussion

This multicenter study analyzed the clinical features of children with MIS-C against control cases of COVID-19 in Thailand. Remarkably, only half of the children with MIS-C in our research exhibited the typical clinical signs or a confirmed COVID-19 diagnosis before developing MIS-C. In contrast, a positive RT-PCR result for SARS-CoV-2 or the detection of antibodies against SARS-CoV-2 was required to validate the MIS-C diagnosis. The comprehensive investigation focused on augmenting the precision of evidence related to COVID-19 infections revealed the presence of COVID-19 antibodies in four study participants. These antibodies act as markers for exposure to COVID-19, even in the absence of clinical manifestations and without definitive confirmation of the virus. This underscores the importance of SARS-CoV-2 antibodies for accurate diagnosis. Moreover, these antibodies were found to be detectable for at least 90 days following the onset of the infection, as noted in prior studies [7]. To effectively differentiate between antibody responses associated with COVID-19 infection, an increase in anti-nucleocapsid antibodies should be employed to delineate COVID-19 infection from post-vaccination responses, which typically demonstrate only anti-spike antibodies [13]. This understanding holds substantial promise for optimizing the timing of diagnoses and enabling early intervention by enhancing comprehension of immune response patterns in relation to COVID-19 exposure.
In terms of demographic data, our findings aligned with earlier studies, showing no significant differences in gender distribution among cases [5,14,15]. Children diagnosed with MIS-C in our study had the median age of 6.7 years, which is lower than what has been reported in previous studies [16,17,18]. The differences in age reported across various studies underscore the unique challenges that children encounter in different regions. This variation can be attributed to the timing of data collection, which affects how and when vaccines are administered in different countries. In Thailand, COVID-19 vaccines have been administered to children over 12 years old since 17 August 2021, and to those aged 5 years and older since 10 February 2022 [19]. COVID-19 vaccines play a crucial role in enhancing immunity and reducing the severity of infections. A study conducted on adults found that after receiving two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine (Kalamazoo, MI, USA), the levels of IgG antibodies surged by over 2000 times at one month after vaccination [20]. Additionally, a study focusing on adolescents aged 12 to 15 demonstrated a 50% increase in immunity against COVID-19 after the second dose, comparable to the 16 to 25 age group [21]. Therefore, a larger proportion of adolescents received vaccinations compared to younger children throughout the duration of this study, resulting in a lower reported median age relative to earlier studies.
In this study, 18 cases (52.9%) reported a history of COVID-19 infection. Previous research has shown a variation in the evidence of COVID-19 infection prior to MIS-C, ranging from 29% to 71% [17,18]. Discrepancies may arise from variations in testing and treatment accessibility across countries, as well as the wide range of COVID-19 symptoms, particularly among children, which can vary from asymptomatic to severe [22]. This variability may result in certain asymptomatic and mild cases not receiving a confirmed diagnosis of COVID-19 infection. In the control group, the most frequently reported clinical symptoms during COVID-19 infection included upper respiratory symptoms, followed by lower respiratory, gastrointestinal, and neurological symptoms, all of which were more prevalent than in the case group. This is likely due to the fact that 47% of the case group had no history of infection, contributing to an underreporting of symptoms.
Regarding factors associated with COVID-19 MIS-C, our findings indicate that antiviral treatment during COVID-19 significantly correlates with a reduction in MIS-C, evidenced by an adjusted OR of 0.06 (95% CI 0.02–0.20). In accordance with the Thai COVID-19 Clinical Practice Guidelines for the diagnosis and treatment of SARS-CoV-2 infection, the antiviral medications administered during the study comprised favipiravir and remdesivir [12]. Children with mild to moderate symptoms who required hospitalization predominantly received favipiravir, which resulted in favorable clinical outcomes and minimal adverse effects, as noted in prior studies [23]. The observed decrease in MIS-C incidence among these children may be attributed to the ability of antivirals like favipiravir and remdesivir to shorten recovery times and modulate the immune response post-infection. A randomized controlled trial involving 1062 hospitalized adults revealed that patients treated with remdesivir had a lower median recovery time of 10 days than those who were administered a placebo, which had an average recovery time of 15 days [24]. Additionally, a systematic review with meta-analysis showed that patients receiving favipiravir had significantly better clinical outcomes compared to the control group after 7 days of hospitalization. However, the viral clearance at 14 days after infection were not statistically significant [25]. Notably, this study is the first to demonstrate a significant connection between antiviral treatment during COVID-19 infection and the occurrence of MIS-C.
The COVID-19 vaccination data analyzed in this study did not demonstrate a statistically significant relationship with the occurrence of MIS-C. However, previous research has indicated that vaccination may contribute to a reduction in the incidence of MIS-C. In earlier studies, it was observed that among MIS-C patients, approximately 10% had received one dose of the COVID-19 vaccine, while around 33% had received two doses. The incidence rate of MIS-C in the previous study was estimated to be approximately 1 case per million vaccinated individuals within the age group of 12 to 20 years [17,26]. The discrepancy in our results may be attributed to the fact that the MIS-C patients in our study were younger than those in earlier studies and may have been recipients of the vaccine later on.
There were several limitations in this study. Firstly, its retrospective nature may result in some gaps in the data collection process. Secondly, the small sample size restricts the possibility of conducting some subgroup analyses. Nonetheless, considering the low prevalence of MIS-C, the calculated sample size for the matched case-control study provided adequate statistical power for the data analysis. Thirdly, some patients diagnosed with MIS-C in this study had a history of COVID-19 exposure rather than confirmation through RT-PCR or antibody testing. Nevertheless, they fulfilled the criteria for MIS-C as outlined by the CDC and WHO. Additionally, details regarding treatment and outcomes were not included in this study. Future research could potentially analyze the effects of remdesivir and favipiravir separately to yield more specific insights and to explore the treatment outcomes among children diagnosed with MIS-C.

5. Conclusions

Receiving antiviral treatment during COVID-19 infection was significantly associated with a reduced incidence of MIS-C in children. Accurate evidence of COVID-19 exposure is crucial for facilitating timely diagnosis and management, thereby enhancing the outcomes for children with MIS-C.

Author Contributions

Conceptualization, B.P., P.S., C.N., C.J. and S.S.; methodology, B.P., P.S., C.N. and S.S.; validation, B.P., P.S., C.N., C.J. and S.S.; formal analysis, B.P. and C.N.; investigation, B.P., P.S. and C.J.; resources, B.P., P.S. and C.J.; data curation, B.P., P.S. and C.N.; writing—original draft preparation, B.P., P.S. and C.N.; writing—review and editing, B.P., P.S., C.N., C.J. and S.S.; visualization, B.P. and P.S.; supervision, C.N. and S.S.; funding acquisition, B.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Medical Council of Thailand (Police General Dr. Jongjate Aojanepong Foundation) and the Chum Phae Hospital Research Fund under the Ministry of Public Health.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Khon Kaen University, Khon Kaen Hospital, and Chum Phae Hospital (EC No. HE661230, KEMOU66011, and HE661001, respectively), approved on 24 April 2024. Permission was obtained from the Disease Control Office 7, Khon Kaen Province, for the collection of COVID-19 vaccination data of the study participants.

Informed Consent Statement

Patient consent was waived due to the retrospective design of the study.

Data Availability Statement

The datasets generated and/or analyzed during the current study are not publicly available but are available from the first author (B.P.) upon request.

Acknowledgments

We express our sincere gratitude to the parents and children, along with all residents, nurses, and staff members, for their valuable support.

Conflicts of Interest

The authors declare that there are no conflicts of interest. The funders played no role in the design of the study, the collection, analysis, or interpretation of data, the writing of the manuscript, or the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:
MIS-CMultisystem Inflammatory Syndrome in Children
CDCCenters for Disease Control and Prevention
SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2
WHOWorld Health Organization
NHSNational Health Service
RCPCHRoyal College of Pediatrics and Child Health
PIM-TSPediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2
CRPC-reactive protein
ESRErythrocyte sedimentation rate
LDHLactate dehydrogenase
IL-6Interleukin-6
IQRInterquartile ranges
95% CI95% confidence interval

References

  1. Cucinotta, D.; Vanelli, M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020, 91, 157–160. [Google Scholar] [CrossRef] [PubMed]
  2. Rehman, S.; Majeed, T.; Ansari, M.A.; Al-Suhaimi, E.A. Syndrome Resembling Kawasaki Disease in COVID-19 Asymptomatic Children. J. Infect. Public Health 2020, 13, 1830–1832. [Google Scholar] [CrossRef] [PubMed]
  3. Abrams, J.Y.; Godfred-Cato, S.E.; Oster, M.E.; Chow, E.J.; Koumans, E.H.; Bryant, B.; Leung, J.W.; Belay, E.D. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. J. Pediatr. 2020, 226, 45–54.e1. [Google Scholar] [CrossRef]
  4. Swann, O.V.; Holden, K.A.; Turtle, L.; Pollock, L.; Fairfield, C.J.; Drake, T.M.; Seth, S.; Egan, C.; Hardwick, H.E.; Halpin, S.; et al. Clinical Characteristics of Children and Young People Admitted to Hospital with COVID-19 in United Kingdom: Prospective Multicentre Observational Cohort Study. BMJ 2020, 370, m3249. [Google Scholar] [CrossRef]
  5. Jiang, L.; Tang, K.; Irfan, O.; Li, X.; Zhang, E.; Bhutta, Z. Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents—A Live Systematic Review and Meta-Analysis. Curr. Pediatr. Rep. 2022, 10, 19–30. [Google Scholar] [CrossRef] [PubMed]
  6. Elsaid, M.; Nune, A.; Hesham, D.; Fouad, F.M.; Hassan, H.; Hamouda, H.; Sherif, H.; Abdelwahab, M.M.; Hegazi, N.; El-Rahman, Y.A. Multisystem Inflammatory Syndrome (MIS) Following SARS-CoV-2 Vaccinations: A Systematic Review. Trop. Dis. Travel Med. Vaccines 2023, 9, 19. [Google Scholar] [CrossRef] [PubMed]
  7. Uppala, R.; Sitthikarnkha, P.; Faksri, K.; Kosalaraksa, P.; Techasatian, L.; Tantawarak, N.; Nanthavongsa, S. Antibodies against SARS-CoV-2 in Unvaccinated Children Hospitalized with COVID-19: An Observational Cohort Study of Pre-Omicron and Omicron Variants Era. PLoS ONE 2024, 19, e0297991. [Google Scholar] [CrossRef]
  8. Hamad Saied, M.; van der Griend, L.; van Straalen, J.W.; Wulffraat, N.M.; Vastert, S.; Jansen, M.H.A. The Protective Effect of COVID-19 Vaccines on Developing Multisystem Inflammatory Syndrome in Children (MIS-C): A Systematic Literature Review and Meta-Analysis. Pediatr. Rheumatol. Online J. 2023, 21, 80. [Google Scholar] [CrossRef]
  9. Parker, R.A.; Bregman, D.J. Sample Size for Individually Matched Case-Control Studies. Biometrics 1986, 42, 919–926. [Google Scholar] [CrossRef]
  10. Zambrano, L.D.; Newhams, M.M.; Olson, S.M.; Halasa, N.B.; Price, A.M.; Orzel, A.O.; Young, C.C.; Boom, J.A.; Sahni, L.C.; Maddux, A.B.; et al. BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 Is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021–April 2022. Clin. Infect. Dis. 2023, 76, e90–e100. [Google Scholar] [CrossRef]
  11. Melgar, M.; Lee, E.H.; Miller, A.D.; Lim, S.; Brown, C.M.; Yousaf, A.R.; Zambrano, L.D.; Belay, E.D.; Godfred-Cato, S.; Abrams, J.Y.; et al. Council of State and Territorial Epidemiologists/CDC Surveillance Case Definition for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection—United States. MMWR Recomm. Rep. 2022, 71, 1–14. [Google Scholar] [CrossRef] [PubMed]
  12. Department of Medical Services, Ministry of Public Health. Thai COVID-19 CPG for Healthcare Workers. Available online: https://www.pidst.or.th/A1176.html (accessed on 2 April 2024).
  13. Al-Shudifat, A.-E.; Al-Tamimi, M.; Dawoud, R.; Alkhateeb, M.; Mryyian, A.; Alahmad, A.; Abbas, M.M.; Qaqish, A. Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients. Vaccines 2023, 11, 1398. [Google Scholar] [CrossRef] [PubMed]
  14. Alkan, G.; Sert, A.; Oz, S.K.T.; Emiroglu, M.; Yılmaz, R. Clinical Features and Outcome of MIS-C Patients: An Experience from Central Anatolia. Clin. Rheumatol. 2021, 40, 4179–4189. [Google Scholar] [CrossRef]
  15. Abrams, J.Y.; Oster, M.E.; Godfred-Cato, S.E.; Bryant, B.; Datta, S.D.; Campbell, A.P.; Leung, J.W.; Tsang, C.A.; Pierce, T.J.; Kennedy, J.L.; et al. Factors Linked to Severe Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C) in the USA: A Retrospective Surveillance Study. Lancet Child Adolesc. Health 2021, 5, 323–331. [Google Scholar] [CrossRef]
  16. Yasuhara, J.; Watanabe, K.; Takagi, H.; Sumitomo, N.; Kuno, T. COVID-19 and Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-Analysis. Pediatr. Pulmonol. 2021, 56, 837–848. [Google Scholar] [CrossRef]
  17. Yousaf, A.R.; Cortese, M.M.; Taylor, A.W.; Broder, K.R.; Oster, M.E.; Wong, J.M.; Guh, A.Y.; McCormick, D.W.; Kamidani, S.; Schlaudecker, E.P.; et al. Reported Cases of Multisystem Inflammatory Syndrome in Children Aged 12–20 Years in the USA Who Received a COVID-19 Vaccine, December, 2020, through August, 2021: A Surveillance Investigation. Lancet Child Adolesc. Health 2022, 6, 303–312. [Google Scholar] [CrossRef]
  18. Bustos, B.R.; Jaramillo-Bustamante, J.C.; Vasquez-Hoyos, P.; Cruces, P.; Díaz, F. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. Pediatr. Emerg. Care 2021, 37, 44–47. [Google Scholar] [CrossRef]
  19. Jantarabenjakul, W.; Chantasrisawad, N.; Nantanee, R.; Ganguli, S.; Puthanakit, T. Global COVID-19 Vaccination in Infants and Children: Effectiveness, Safety, and Challenges. Asian Pac. J. Allergy Immunol. 2023, 41, 292–303. [Google Scholar] [CrossRef] [PubMed]
  20. Kotaki, R.; Adachi, Y.; Moriyama, S.; Onodera, T.; Fukushi, S.; Nagakura, T.; Tonouchi, K.; Terahara, K.; Sun, L.; Takano, T.; et al. SARS-CoV-2 Omicron-Neutralizing Memory B Cells Are Elicited by Two Doses of BNT162b2 mRNA Vaccine. Sci. Immunol. 2022, 7, eabn8590. [Google Scholar] [CrossRef]
  21. Frenck Robert, W.; Klein Nicola, P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez John, L.; Walter Emmanuel, B.; Senders, S.; Bailey, R.; et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents. N. Engl. J. Med. 2021, 385, 239–250. [Google Scholar] [CrossRef]
  22. Tagarro, A.; Cobos-Carrascosa, E.; Villaverde, S.; Sanz-Santaeufemia, F.-J.; Grasa, C.; Soriano-Arandes, A.; Hernanz, A.; Navarro, M.L.; Pino, R.; Epalza, C.; et al. Clinical Spectrum of COVID-19 and Risk Factors Associated with Severity in Spanish Children. Eur. J. Pediatr. 2022, 181, 1105–1115. [Google Scholar] [CrossRef] [PubMed]
  23. Sitthikarnkha, P.; Phunyaissaraporn, R.; Niamsanit, S.; Techasatian, L.; Saengnipanthkul, S.; Uppala, R. Clinical Characteristics and Outcomes of Pediatric COVID-19 Pneumonia Treated with Favipiravir in a Tertiary Care Center. Viruses 2024, 16, 946. [Google Scholar] [CrossRef] [PubMed]
  24. Beigel John, H.; Tomashek Kay, M.; Dodd Lori, E.; Mehta Aneesh, K.; Zingman Barry, S.; Kalil Andre, C.; Hohmann, E.; Chu Helen, Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of COVID-19—Final Report. N. Engl. J. Med. 2020, 383, 1813–1826. [Google Scholar] [CrossRef] [PubMed]
  25. Hassanipour, S.; Arab-Zozani, M.; Amani, B.; Heidarzad, F.; Fathalipour, M.; Martinez-de-Hoyo, R. The Efficacy and Safety of Favipiravir in Treatment of COVID-19: A Systematic Review and Meta-Analysis of Clinical Trials. Sci. Rep. 2021, 11, 11022. [Google Scholar] [CrossRef]
  26. Payne, A.B.; Gilani, Z.; Godfred-Cato, S.; Belay, E.D.; Feldstein, L.R.; Patel, M.M.; Randolph, A.G.; Newhams, M.; Thomas, D.; Magleby, R.; et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw. Open 2021, 4, e2116420. [Google Scholar] [CrossRef]
Children 12 00678 g001
Figure 1. The distributions of (A) platelet count, (B) white blood cell count, (C) absolute neutrophil count, and (D) absolute lymphocyte count during COVID-19 infection among MIS-C case children and hospitalized control children with COVID-19 infection.
Figure 1. The distributions of (A) platelet count, (B) white blood cell count, (C) absolute neutrophil count, and (D) absolute lymphocyte count during COVID-19 infection among MIS-C case children and hospitalized control children with COVID-19 infection.
Children 12 00678 g001
Table 1. Demographic characteristics among MIS-C case children and hospitalized control children with COVID-19 infection.
Table 1. Demographic characteristics among MIS-C case children and hospitalized control children with COVID-19 infection.
VariableMIS-C Group
(n = 34)		Control Group
(n = 68)		p-Value
Gender, n (%) 1
Female16 (47.1%)32 (47.1%)
Male18 (52.9%)36 (52.9%)
Age at the time of COVID-19 infection (years), median (IQR)6.7 (3.1, 11.8)5.8 (2.9, 10.5)0.64
Percentage of weight for height, median (IQR)94.5 (84.5, 108.5)101.1 (89.2, 119.6)0.23
Nutrition status, n (%) 0.63
Normal13 (38.2%)27 (39.7%)
Malnutrition13 (38.2%)18 (26.5%)
Overweight5 (14.7%)15 (22.1%)
Obesity3 (8.8%)8 (11.8%)
Received COVID-19 vaccination, n (%) 0.26
No25 (73.5%)47 (69.1%)
1 dose4 (11.8%)16 (23.5%)
More than 1 doses5 (14.7%)5 (7.4%)
Durationafter 1st dose of vaccine and COVID-19 infection (days), median (IQR)42 (32, 122)71 (22, 118)0.88
Duration after 2nd dose of vaccine and COVID-19 infection (days), median (IQR)175 (132, 217)91.5 (83, 103)0.53
Duration after last dose of vaccine and COVID-19 infection (days), median (IQR)42 (32, 59)86 (29, 114)0.35
Duration after 1st dose of vaccine and MIS-C diagnosis (days), median (IQR)149 (56, 334)--
Duration after 2nd dose of vaccine and MIS-C diagnosis (days), median (IQR)309 (127, 533)--
Duration after last dose of vaccine and MIS-C diagnosis (days), median (IQR)109 (56, 127)--
Table 2. Clinical characteristics during hospitalized from COVID-19 infection the case of group with MIS-C and control group.
Table 2. Clinical characteristics during hospitalized from COVID-19 infection the case of group with MIS-C and control group.
VariableMIS-C Group
(n = 18)		Control Group
(n = 68)		p-Value
Upper respiratory tract symptoms, n (%)6 (33.3%)43 (64.2%)0.019
Lower respiratory tract symptoms, n (%)5 (27.8%)41 (60.3%)0.014
Gastrointestinal tract symptoms, n (%)2 (11.1%)14 (20.6%)0.51
Fever, n (%)12 (66.7%)45 (66.2%)0.97
COVID-19 severity, n (%) 0.05
Mild16 (88.9%)52 (76.5%)
Moderate1 (5.6%)16 (23.5%)
Severe1 (5.6%)0 (0.0%)
COVID-19 complication, n (%)1 (5.6%)4 (5.9%)1
White blood cell count (cells/mm3), median (IQR)8300 (7315, 8915)7750 (5655, 9185)0.48
Absolute neutrophil count (cells/mm3), median (IQR)5746 (4847, 6193)2905 (2051, 4591)0.12
Absolute lymphocyte count (cells/mm3), median (IQR)996 (882, 1660)2949 (1907, 4551)0.041
Blood platelets (cells/mm3), median (IQR)145,000 (140,000, 176,000)287,000 (253,000, 317,500)0.011
Received anti-viral therapy during COVID-19 infection, n (%)8 (44.4%)53 (77.9%)0.005
Table 3. Univariate and multivariate analyses reflecting factors associated with MIS-C in children.
Table 3. Univariate and multivariate analyses reflecting factors associated with MIS-C in children.
VariablesCrude OR (95% CI)Adjusted OR (95% CI)
Received anti-viral therapy during COVID-19 infection
Not receivedReferenceReference
Received0.13 (0.06–0.30)0.06 (0.02–0.20)
Nutritional status
NormalReferenceReference
Malnutrition1.37 (0.63–2.96)0.79 (0.23–2.70)
Overweight0.74 (0.26–2.07)0.93 (0.22–3.96)
Obesity0.81 (0.23–2.85)0.44 (0.07–2.92)
Coronavirus 2019 vaccine
Not receivedReferenceReference
Received 1 dosed0.50 (0.17–1.51)0.28 (0.06–1.27)
Received at least 2 doses1.53 (0.57–4.12)1.83 (0.34–9.89)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Prasertsakul, B.; Sitthikarnkha, P.; Ngamjarus, C.; Jakeaw, C.; Sutra, S. Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study. Children 2025, 12, 678. https://doi.org/10.3390/children12060678

AMA Style

Prasertsakul B, Sitthikarnkha P, Ngamjarus C, Jakeaw C, Sutra S. Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study. Children. 2025; 12(6):678. https://doi.org/10.3390/children12060678

Chicago/Turabian Style

Prasertsakul, Buddhaporn, Phanthila Sitthikarnkha, Chetta Ngamjarus, Chaniya Jakeaw, and Sumitr Sutra. 2025. "Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study" Children 12, no. 6: 678. https://doi.org/10.3390/children12060678

APA Style

Prasertsakul, B., Sitthikarnkha, P., Ngamjarus, C., Jakeaw, C., & Sutra, S. (2025). Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study. Children, 12(6), 678. https://doi.org/10.3390/children12060678

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop